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ABSTRACT 
Introduction: Sentinel lymph node biopsy (SLNB) is an important adjunct in the staging of 
patients with melanoma. Preoperative lymphoscintigraphy (LS) with radiolabeled isotopes is 
essential to localize sentinel nodes for removal. Our study compared the effectiveness of 
Lymphoseekto standard sulfur colloids (SC) in patients with melanoma undergoing SLNB. 
Methods: We queried our IRB-approved melanoma database to identify 370 consecutive 
patients who underwent SLNB from 2012-2016 with at least one year of follow up. There were 
185 patients in each group. Data points included characteristics of the primary melanoma 
lymphoscintigraphy, and SLNB. Student’s t-test and Chi-Square were used to analyze the data 
with a p-value of <0.05 being considered significant. 
Results: Patients were equally matched in regard to age, sex, and primary characteristics of their 
melanoma. In comparison to SC, Lymphoseekrequired lower radiation dosages (p<0.001), 
shorter mapping times (p=0.008), and decreased number of sentinel nodes removed (p=0.03). 
There was no difference in the number of patients with positive nodes (p=0.5). Additionally, 
there were no statistical differences between the two radioactive tracers in regard to the number 
of patients with false negative SLNB. 
Conclusion: Lymphoseekhas the potential to decrease radioactivity and mapping time in 
patients who need SLNB. With a decrease in the number of nodes removed without loss of 
sensitivity, there is a potential to avoid unnecessary node removal and thus complications such as 
lymphedema. Longer follow-up will help to determine if there is any increase in false negative 
rates despite fewer nodes removed. 
Key Words: Melanoma, sentinel lymph node, lymphoscintigraphy, radiocolloids
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INTRODUCTION 
 
 Sentinel lymph node biopsy (SLN) biopsy has been established as the standard of care for 
staging patients with intermediate-thickness (>1mm) cutaneous melanoma. SLN mapping allows 
for the identification of lymph nodes draining the lymphatic pathway from the primary tumor. 
Typically, two types of agents are used in this mapping—vital blue dyes such as Lymphazurin 
which stain the sentinel nodes blue and radiopharmaceuticals which are tracked with 
lymphoscintigraphy. The most commonly used radiopharmaceuticals used in the United States 
are large molecular weight radiocolloids, such as 99mTc-labeled sulfur colloid (SC). Due to their 
large size, radiocolloids are slowly cleared from the injection site resulting in delayed migration 
to the lymphatics and this retention may mask regionally located lymph nodes in some instances. 
Radiocolloids can also be associated with notable injection site pain.  
 99mTc-tilmanocept (Lymphoseek) is a novel molecular agent which accumulates in 
lymphatic tissue by binding mannose receptors residing on the surface of lymphatic 
reticuloendothelial cells (1). It was approved by the Food and Drug Administration for lymphatic 
mapping in solid tumors in 2014 (1) and is being used more now in patients with breast cancer, 
melanoma, and squamous cell carcinoma of the head and neck. The novel radiotracer 
Lymphoseek provides advantages over blue dyes and radiocolloids due to its structure. 
Lymphoseek displays rapid uptake and retention within SLNs, and its small diameter permits 
rapid injection site clearance. Compared to radiocolloids, Lymphoseek is also associated with 
decreased injection site pain (2). In this study, we sought to compare the efficacy of 
Lymphoseek to the standard radiocolloids used during SLNB procedures at our institution since 
we began using Lymphoseekin July of 2014.   
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METHODS 
 
 Following Thomas Jefferson University Institutional Review Board approval with a 
waiver of informed consent, we performed a retrospective chart review and identified 
consecutive patients who underwent SLNB between 2012 and 2016 and had at least one year of 
follow up. The following data points were collected. For the primary tumor, we evaluated the 
primary site, Breslow thickness, and whether the tumor was ulcerated. For the 
lymphoscintigraphy, we reviewed reports and films to identify the dosage of radiotracer, the 
mapping time, and the number of hot spots identified in each patient. Finally, for the SLNB, we 
recorded the number of sentinel nodes removed and the number of positive sentinel nodes.  
SLN Mapping and Biopsy  
All of the procedures were performed by two authors (JCK and ACB). Sentinel lymph 
node biopsies were performed using the following technique.  Patients received intradermal 
injection of 4 doses of ~150 microcuries 99mTc sulfur colloid or 4 doses of ~125 microcuries of 
Lymphoseekon the morning of surgery followed by lymphatic mapping to locate the lymph 
node drainage basin. All patients underwent full body scanning after injection with SC or 
Lymphoseek. To determine the mapping time, we reviewed all images and reports to identify 
how long patients were mapped as well as when the last radiograph was taken (Figure 1). We did 
not evaluate when the first node was imaged.  Intraoperatively, patients received intradermal 
injection of either 1 ml of isosulfan blue (LymphazurinTM 1%; Tyco International, Exeter, NH) 
or 1 ml of methylene blue at the site of the primary tumor. This was followed by a brief massage 
of the overlying skin to enhance lymphatic drainage of the injected dye.  Radioactivity of the 
labeled lymph nodes was measured during surgery using a handheld gamma probe.  SLN were 
defined as those containing blue dye, those with the highest counter on the gamma probe, or any 
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node that had greater than 10% radioactivity as compared to the hottest node.  All SLN were 
removed and sent for pathological evaluation.  
Pathologic evaluation of lymph nodes 
All identifiable lymph nodes were entirely submitted. Two deeper hematoxylin and eosin 
(H&E) stained sections were prepared from the formalin-fixed, paraffin embedded blocks, about 
8-12 microns between each level, and depending on size of lymph node, multiple sections were 
placed on each slide.  If no tumor is seen on initial routine sections, then a panel of 
immunohistochemical antibodies was analyzed including any one or more of the following 
antibodies: S-100, Melan A, HMB-45, and more recently SOX-10.  
Patients were considered to have a false-negative sentinel lymph node biopsy (FN-
SLNB) if they developed LN recurrence in a LN basin where a sentinel node biopsy was 
previously performed or in a basin where mapping could theoretically occur. For example, in a 
patient with a melanoma on the mid-lateral trunk that mapped to the axilla but then recurred in 
the groin on the same side, we considered that to be a FN-SLNB. We did not consider patients 
who developed satellite, in-transit, and/or systemic metastases at the same time as a regional LN 
recurrence to have a FN-SLNB because of the possibility that these metastases could have led to 
the regional LN involvement.  
Statistical Analysis 
 
To evaluate the differences between the SC and Lymphoseekgroup t-tests were 
performed with a p-value less than or equal to 0.05 being considered significant. Additionally, a 
chi-squared test was used to evaluate the rate of false negative between the two groups. 
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RESULTS 
 
 Between 2012 and 2016, we identified a total of 370 patients who underwent sentinel LN 
biopsy in this cohort with 185 patients in each group. Characteristics of the entire population are 
demonstrated in Table 1. When comparing the sulfur colloid (SC) group and the 
Lymphoseekgroup, the average patient age was 59.6 and 60.9 and in both groups, there were 
more males than females (60.5% and 56.2%), respectively. The distribution of primary 
melanoma sites was fairly equal with melanomas of the trunk, extremity, and head and neck 
having equal representation in both groups. There were two and one patients respectively with 
subungal primary sites. The average Breslow thickness was similar with 2.9 (range=0.3-37mm) 
and 2.6 (range=0.35-45mm), respectively. The number of melanomas with ulceration present 
was also similar between the two groups. The median follow-up time was significantly longer in 
the SC group which was treated in the earlier years of this study (Table 1). 
 Being that the two groups were matched in regards to demographic characteristics, we 
sought to evaluate differences between the groups regarding sentinel lymph nodes and 
lymphoscintigraphy procedures. (Table 2). All patients underwent full body scanning after 
injection with SC or Lymphoseek. Images and reports were all reviewed. The dose of 
radioactivity used for injection was significantly lower in the Lymphoseekgroup (503 vs. 580 
µCi, p<0.0001).  The average mapping was significantly lower in the Lymphoseekgroup (31 vs. 
34 minutes, p<0.008). We also evaluated differences in mapping time by determining the number 
of patients who had mapping for longer than 30 minutes. In the SC group, the vast majority of 
patients (n=129, 70%) had mapping times of 30 minutes or greater compared to 109 (59%) in the 
Lymphoseekgroup; this difference was significantly different as well (p=0.04).  
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Additionally, we attempted to identify the number of hot spots per lymph node drainage 
basin. There was no statistical difference between the two groups in this regard (2.3 vs. 2.4, 
p=0.1, Table 2). There were four patients in the SC group and six patients in the 
Lymphoseekgroup who did not have any lymph nodes or hot spots identified on mapping 
(p=0.75). In all of these patients, we were able to identify sentinel nodes with use of the 
Neoprobe and blue dye. There was no specific pattern regarding the primary sites for these 
mapping failures (two chest, one arm, one foot for SC group; three arms, one neck, one chest, 
and an abdominal wall for the Lymphoseekgroup) 
  We found that the average total number of sentinel nodes removed per patient was 
higher in the SC group compared to Lymphoseek (2.9 vs 2.5). While this was statistically 
significant (p=0.03), the clinical significance of this is difficult to determine. If we look at the 
number of patients with more than 5 SLNs removed, there is a non-significant difference 
between SC (n=25) and Lymphoseek (n=17). There were 28 patients with positive sentinel 
lymph nodes (15%) in the SC group 23 (12%) in the Lymphoseekgroup which was not 
significantly different (p=0.5). Finally, we looked back to determine whether there was any 
differences in rates of recurrence in the mapped basin for patients with a negative sentinel lymph 
node. If we see a difference in this false negative rate, it could indicate some compromise in the 
integrity of the mapping. Here we found that the false-negative SLNB rates were equal between 
the two cohorts ((1.6%) vs. (1.0%), p=1.0).  
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DISCUSSION 
The results from this study indicate that Lymphoseek (99Tc-tilmanocept) is able to 
identify sentinel nodes in patients undergoing lymphoscintigraphy for melanoma in a shorter 
amount of time and with less radioactivity than patients mapped with 9Tc-Sulfur Colloid. 
Additionally, with fewer sentinel lymph nodes removed, there is theoretically a decreased 
likelihood of lymphedema; with short-term follow-up, there is also no decrement in sensitivity 
with equal number of false negative cases. The number of positive nodes removed per patient 
was not different, and there was not a significant difference between the percentage of patients 
with positive nodes.  
Despite there not being a difference in the average number of hot spots per basin seen on 
lymphoscintigraphy, we did find a significant difference in the average number of SLNs 
removed. This may be explained by Lymphoseek’s specificity for CD206 which allows it to stay 
bound to the first lymph node and not have downstream migration. With fewer secondary nodes 
taking up the technetium, theoretically, there should be fewer nodes removed. We acknowledge 
that there is probably not a clinical significant difference between 2.9 and 2.5 nodes. However, it 
is possible that if you extrapolate this difference out over thousands of patients, this could 
become a more meaningful clinical difference. The same is true regarding whether this may 
possibly contribute to the likelihood of lymphedema. It is interesting to note that there was not a 
significant difference in the number of hot spots seen on lymphoscintigraphy between the 
groups, yet there was a difference in the number of nodes removed. It is possible that there were 
smaller, secondary sentinel nodes that took up the technetium sulfur colloid that were removed at 
the time of the sentinel node biopsy which led to the increase in the total number of nodes 
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removed. In the end, because this is a retrospective study, we do not have a good explanation for 
this finding and acknowledge that it is a limitation of this study. 
99Tc-tilmanocept is a novel radiopharmaceutical which accumulates in lymphatic tissue 
by selectively targeting and binding to CD206 receptors on the surface of macrophages and 
dendritic cells; these are found in high concentrations in lymph nodes (1). The mannose residue 
on the tilmanocept serves as a ligand for the CD206 receptor. Furthermore, targeted receptor 
binding limits its migration into distal lymph nodes (3). The average diameter of the 99Tc-
tilmanocept molecule is 7nm—this small size allows for rapid lymphatic uptake (1). On the other 
hand, filtered 99Tc-SC particles (which is what we and most investigators in the US use) are 
between 100 and 200nm (1).  
The FDA approval of Lymphoseekfor the use in lymphatic mapping for solid tumors 
followed several clinical trials which demonstrated superior performance over filtered SC.  
Baker et al performed a study comparing mapping with tilmanocept and blue dye versus SC with 
blue dye in breast cancer patients (4). They found that fewer SLNs were removed in the 
tilmanocept patients (p<0.0001) which is similar to what we found in our study. Two non-
randomized phase III trials compared tilmanocept with blue dye for identification of SLN in 
melanoma patients. In these studies, tilmanocept identified 232 of 235 blue nodes (98.7% 
concordance); tilmanocept detected 364 nodes only 232 of which were detected by blue dye 
(64% reverse concordance) (5). Additionally, in this study, tilmanocept identified more positive 
nodes than blue dye. Similar results were seen in a phase III study in patients with breast cancer 
(6). Finally, a multi-center phase III trial in cutaneous or intraoral squamous cell carcinoma of 
the head and neck demonstrated a high overall accuracy and low false-negative rate for 
Lymphoseek (7).  
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One of the important differences that exist between SC and Lymphoseekis the 
differences in injection site pain. Because of the retrospective nature of this trial, we were not 
able to effectively evaluate that parameter. However, a recent randomized trial in breast cancer 
patients showed a significant decrease in pain scores for patients injected with 
Lymphoseekcompared to SC (2). In this study, 52 patients were randomized between the two 
radiocolloids. The investigators found that at one, two, and three minutes post injection, the 
Lymphoseekpatients had significantly lower pain scores using the visual analog scale (2). Other 
investigators have attempted to ameliorate the pain associated with SC injection with addition of 
lidocaine and bicarbonate to SC (8), separate lidocaine injection (9), or topical anesthetic cream 
(10) with mixed success. 
It is not completely clear why SC induces significantly more pain at the injection site. It 
was thought that this may be due to the pH of the agents. However, in the Stojadinovic study, 
there was no change in pain scores when the pH of SC was altered by mixing with bicarbonate 
(8). One possible reason for the increased pain could be the particle size. The small size of 
Lymphoseekparticles allows for their rapid transit away from the injection site. Additionally, it 
is postulated that the larger size of the SC particles may increase the stretch on the nocioceptive 
pain receptors in the dermis leading to patients experiencing a more intense pain (2).  
In regards to shorter mapping times, even though we found a significant difference in 
mapping times, in reality, there was only a three minute difference. In previously unpublished 
work from our institution (presented at the 2015 meeting of the Radiologic Society of North 
America), we found that all 34 patients evaluated had reached the maximum number of 
identified lymph nodes at 20 minutes as opposed to the 40-45 minutes that most patients with SC 
were undergoing imaged. Additionally, when we look at our data set, in the SC group, the vast 
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majority of patients had mapping times of 30 minutes or greater compared to the 
Lymphoseekgroup; this difference was significantly different as well (p=0.04). It is our hope 
that now that we have established our experience with Lymphoseek that we can cut short our 
mapping times at a maximum of 20 minutes. This has the ability to move patients through the 
system faster with fewer operating room delays and greater patient satisfaction. It is not our 
routine practice to have patients undergo lymphoscintigraphy the day before their operation 
because in our academic referral practice, the majority of our patients live a considerable 
distance away.  
We would like to acknowledge several limitations of our study. First of all, this is a non-
randomized study which relied on a consecutive series of patients from before and after the time 
that our institution switched over to using Lymphoseekexclusively. Secondly, our follow-up 
times for the Lymphoseekpatients are significantly shorter (25.2 versus 5.4 months) because 
these patients were only operated on in the last 3 years. Even though our false-negative rate was 
no different between the two groups, this may change with longer follow-up in the 
Lymphoseekgroup. Finally, our mapping times are pulled from radiology reports. We did not 
go back to prospectively evaluate every lymphoscintigraphy study to determine whether there 
was additional benefit in the number of nodes identified with longer mapping times. We did not 
perform a formal cost analysis in this study. The cost of Lymphoseekis significantly more than 
sulfur colloid ($522.00 vs. $74.18). Our hope is that with more experience we will be able to 
have patients go through the Nuclear Medicine Department faster with less pain, and this will 
justify the increased cost.  
In conclusion, it is felt that the ideal lymph node mapping agent should exhibit rapid 
clearance from the injection site, rapid uptake within the first draining lymph node as well as low 
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uptake by the remaining lymph nodes. It should also have a low radiation dose and absorption 
(11). This study, albeit a small non-randomized one, has demonstrated that 
Lymphoseekdemonstrates these characteristics. Our institution is using this agent for mapping 
in all melanoma, Merkel Cell carcinoma, and most breast cancer patients.    
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TABLES AND FIGURES 
 
Table 1. Patient Demographics and Summary Statistics 
 
 Sulfur Colloid Lymphoseek 
N (%) 185 (50%) 185 (50%) 
Age, years 
(average, range) 
59.6 (18-89) 60.9 (24-87) 
Sex   
     Male 112 104 
     Female 72 81 
     (Male: Female) 1.5:1 1.3:1 
Breslow, mm (average) 2.9 2.6 
Presence of Ulceration   
      Ulcerated 48 43 
      Non-ulcerated 135 130 
AJCC Stage Group   
Ia 28 22 
Ib 71 75 
IIa 20 33 
IIb 27 24 
IIc 11 8 
IIIa 12 14 
IIIb 16 9 
Primary Site   
       Head/neck 20 22 
       Trunck 85 76 
       Extremity 87 86 
       Subungal 2 1 
Median Follow-up Time 
(months) 
25.2 5.4 
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Table 2. Mapping and SLN Biopsy Characteristics 
 
  Sulfur Colloid  
(n=185, 50%) 
Lymphoseek  
(n=185, 50%) 
p value 
Average Dosage, 
uCi 
580.5 503 <0.0001 
Average Mapping 
Time, minutes  
 (range) 
33.6 
(5-65)                                   
30.7  
(10-60) 
  
0.008 
# of patients with 
mapping > 30 min 
129 (70%) 109 (59%) 0.04 
Average number of 
hot spots/basin  
2.3 2.4 0.10 
Average total 
number SLN 
removed 
2.9 2.5 0.035 
Number patient 
with + sentinel 
nodes  
28 (15.1%) 23 (12.4%) 0.5 
Number of False 
Negatives 
3 2  P=1.0 
 
